Trevi Therapeutics, Inc.
- TRVI
- NASDAQ
- Biotechnology
- Clinical-Stage Biopharma
- Pain/Neurology Treatments
$11.88
Today −1.90%Quote Oct 16, 2026, 08:00 PM UTC
−21.89%over the last month
Max drawdown −22.0%From 1-month high −22.0%3 months −29.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.69B
Quote Oct 16
Next earnings
Nov 12
Expected, not confirmed
Analyst target
$29.67
+149.7% from here
Floor
$11.43
3.8% below price
Where the price sits
18 analysts
Analyst range, low to high
$23.00$40.00
- Price $11.88
- Resistance $12.31
- Consensus $29.67
Analysts' average target sits about 150% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TRVIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
34